Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Background: A person s tumor is studied for mutations. When cells are found that can attack the mutation in a person s tumor, the genes from those cells are studied to find the parts that make the attack possible. White blood cells are then taken from the person s body, and the gene transfer occurs in a laboratory. A type of virus is used to transfer the genes that make those white blood cells able to attack the mutation in the tumor. The gene transfer therapy is the return of those white blood cells back to the person. Objective: To see if gene transfer therapy of white blood cells can shrink tumors. Eligibility: People with certain metastatic cancer for which standard treatments have not worked. Design: Participants may complete screening under another protocol. Screening includes: * Getting tumor cells from a previous procedure * Medical history * Physical exam * Scans * Blood, urine, heart, and lung tests The study has 8 stages: 1. Screening tests repeated over 1-2 weeks. Participants will have leukapheresis: Blood is removed by a needle in one arm. A machine removes white blood cells. The rest of the blood is returned by a needle in the other arm. 2. Care at home over approximately 12 weeks. 3. Stopping therapy for 4-6 weeks while their cells are changed in a lab. 4. Hospital stay approximately 3-4 weeks for treatment. An IV catheter will be placed in the chest to administer drugs. 5. Patients on Arm 2 of the study will receive the first dose of pembrolizumab while in the hospital. Three additional doses will be given after the cell infusion 3 weeks apart. 6. Receiving changed cells by catheter. Then getting a drug over 1-5 days to help the cells live longer. 7. Recover in the hospital for 1-2 weeks. Participants will get drugs and have blood and urine tests. 8. Participants will take an antibiotic and maybe an antiviral for at least 6 months after treatment. They will have repeat screening tests at visits every few months for the first year, every 6 months for the second year, then as determined.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby z niektórymi rodzajami zaawansowanego raka, który nie zareagował na standardowe leczenie.
- •Rak, który można zmierzyć i który dotyczy określonych typów nowotworów (m.in. z przewodu pokarmowego, moczowo-płciowego, piersi, jajnika, płuca, guzów endokrynnych, szpiczaka mnogiego).
- •Rak zdiagnozowany i potwierdzony.
- •Standardowe leczenie okazało się nieskuteczne.
- •Osoby, które otrzymały określone wcześniejsze terapie (wymienione w kryteriach, np. chemioterapia, leczenie celowane).
- •Osoby z maksymalnie trzema (3) niewielkimi (poniżej 1 cm) i nie dającymi objawów przerzutami do mózgu, które były leczone i są stabilne.
✗ Disqualifies
- •Osoby, których rak nie spełnia powyższych kryteriów dotyczących typu lub rozległości.
- •Osoby, które nie przeszły wymaganych wcześniejszych terapii lub których rak nie był na nie oporny.
- •Osoby z więcej niż trzema (3) lub większymi/objawowymi przerzutami do mózgu.
- •Osoby w złym stanie ogólnym, który uniemożliwia przyjęcie proponowanego leczenia.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 72 Years
- Last updated (source)
- July 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
National Institutes of Health Clinical Center
Bethesda, United States
Trial contact
NCI SB Immunotherapy Recruitment Center
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.